支持抗补体治疗在膜性肾病中应用的证据
该研究通过激光捕获显微切割和质谱分析发现,原发性膜性肾病患者肾小球中补体成分C3、C4及膜攻击复合物成分升高,而补体调节蛋白CR1降低;尿液Ba、C5a和C5b-9水平升高且相互相关,提示补体参与膜性肾病发病,抗补体治疗可能有效。
要点
- 膜性肾病患者肾小球补体成分沉积,调节蛋白CR1减少。
- 尿液补体活化产物升高且高度相关,提示补体激活。
- 补体参与发病支持抗补体治疗可能对部分患者有效。
核心结论
- 肾小球C3、C4及MAC成分升高伴CR1降低,尿液补体活化产物增加,支持补体参与膜性肾病发病。
- 这些数据提示抗补体治疗可能对某些类型的膜性肾病有效。
研究设计与样本
- 研究纳入两个独立原发性膜性肾病队列,分别进行肾小球质谱分析和尿液补体产物检测。
- 队列1:激光捕获显微切割后质谱分析肾小球补体蛋白,pMN患者n=11,正常对照n=5。
- 队列2:pMN患者n=13,检测尿液Ba、C5a和C5b-9水平。
主要发现
- 质谱鉴定出8种补体通路成分(C1q、C3、C4、C5、C6、C7、C8、C9)和5种补体调节蛋白(CR1、FH、FHR2、玻璃粘连蛋白、簇集素)。
- 除CR1水平较低外,膜性肾病组所有补体水平显著高于对照组。
- 所有pMN活检标本C1q染色阴性或微量,C3和C4染色阳性,且至少一种凝集素途径成分染色阳性。
临床怎么用
- 对原发性膜性肾病患者,可关注肾小球补体沉积和尿液补体活化产物。
- 抗补体治疗可能成为部分膜性肾病患者的潜在治疗选择。
局限性
- 研究样本量较小(pMN队列分别为n=11和n=13)。
- 补体在人类膜性肾病中的作用尚未完全明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Membranous nephropathy (MN) is a common cause of adult nephrotic syndrome that progresses to end-stage kidney disease in up to 40% of cases. It is an autoimmune disease characterized by glomerular subepithelial deposits containing IgG. In experimental MN, these deposits activate complement and cause kidney damage. The role of complement in human MN is less clearly defined. To address this, the current study focused on the role of complement in 2 independent primary (p) MN cohorts. METHODS: Glomeruli were isolated by laser capture microdissection and analyzed by mass spectrometry, focusing on complement proteins, from kidney biopsy specimens from a pMN cohort (n = 11) and from normal controls (n = 5). Immunohistological staining of kidney biopsy specimens for complement proteins was also done. In a second pMN cohort (n = 13), urine levels of Ba, C5a, and C5b-9 (membrane attack complex [MAC]) were measured. RESULTS: Mass spectrometry identified 8 complement pathway components (C1q, C3, C4, C5, C6, C7, C8, and C9) and 5 complement regulators (complement receptor type 1 [CR1], factor H [FH], FH-related protein 2 [FHR2], vitronectin, and clusterin). All complement levels were significantly higher in the MN groups than in the control group, except the level of CR1, which was lower. All pMN biopsy specimens showed negative or trace staining for C1q, positive staining for C3 and C4, and positive staining for at least 1 component of the lectin pathway. Urine Ba, C5a, and MAC were present in pMN, and their levels correlated (r Ba,C5a = 0.87, r Ba,MAC = 0.89, and r C5a,MAC = 0.97, P = .001 for each correlation). CONCLUSION: Elevated glomerular levels of C3, C4, and components of MAC (C5b-9) and absent or decreased levels of the complement regulator CR1, along with increased levels of complement activation products in the urine, support the involvement of complement in the pathogenesis of MN. These data raise the possibility that anti-complement therapies may be effective in some forms of MN.
引用
- Ayoub I, Shapiro JP, Song H, et al. Establishing a Case for Anti-complement Therapy in Membranous Nephropathy. Kidney Int Rep. 2020. PMID: 33615073. doi:10.1016/j.ekir.2020.11.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。